Robert Straka

COP - Image - Size 3 - COP - straka robert

Robert Straka, B.Sc., Pharm.D., FCCP

Academic Title

Professor and Department Head
Experimental and Clinical Pharmacology

Education

Pharmacy School
Pharm.D. College of Pharmacy, University of Minnesota, 1985
Fellowship
Cardiovascular Pharmacokinetics, University of Tennessee, 1987
Bachelor's
Pharmacy, University of Toronto, Ontario, Canada, 1983
Other Education
Sabbatical, Cardiovascular Pharmacogenomics, University of Florida, 2006-2007

Contact Info

Email
strak001@umn.edu

Phone
612-624-5663

Fax
612-625-3927

Administrative Contact

Dede Johnston

Office Address

7- 115B Weaver-Densford Hall

Mailing Address

University of Minnesota
College of Pharmacy
Department of Experimental and Clinical Pharmacology
7-115 Weaver-Densford Hall
308 Harvard St. SE
Minneapolis, MN 55455

Research Interests

  • Cardiovascular Pharmacotherapy
  • Pharmacogenomics
  • Pharmacodynamics and Pharmacokinetics
  • Drug Metabolism
     

Research Projects

My research interests are focused on optimizing the use of therapeutic agents used for the prevention and treatment of cardiovascular disease by investigating pharmacogenetic, pharmacokinetic and pharmacodynamic sources of variability in drug response. Although primarily interested in cardiovascular therapeutics (eg the GOLDN Study), my investigations have included environmental sources of variability in response as well as therapeutic agents used to treat conditions other than cardiovascular disease. We are also interested in research related to ethnicity-based sources of drug response variability. Understanding sources of variability in drug response may prove helpful in optimizing the achievement of therapeutic targets - a goal which is common to all those interested in optimizing clinical outcomes.

Therapeutic Areas of Interests

Hyperlipidemia, Hypertension, Metabolic Syndrome and Heart Failure

Downloads

Links 

 

Publications

An P, Straka RJ, Pollin TI, Feitosa MF, Wojczynski MK, Daw EW, O'Connell JR, Gibson Q, Ryan KA, Hopkins PN, Tsai MY, Lai CQ, Province MA, Ordovas JM, Shuldiner AR, Arnett DK, Borecki IB. Genome-wide association studies identified novel loci for non-high-density lipoprotein cholesterol and its postprandial lipemic response. Hum Genet. 2014 Jul;133(7):919-30. doi: 10.1007/s00439-014-1435-3. PMID: 24604477

Feitosa MF, Wojczynski MK, Straka R, Kammerer CM, Lee JH, Kraja AT, Christensen K, Newman AB, Province MA, Borecki IB. Genetic analysis of long-lived families reveals novel variants influencing high density-lipoprotein cholesterol. Front Genet. 2014 Jun 3;5:159. doi: 10.3389/fgene.2014.00159. eCollection 2014. PMID 24917880

Oldenburg NC, Duval S, Luepker RV, Finnegan JR, LaMarre H, Peterson KA, Zantek ND, Jacobs G, Straka RJ, Miller KH, Hirsch AT.A 16-month community-based intervention to increase aspirin use for primary prevention of cardiovascular disease.Prev Chronic Dis. 2014 May 15;11:E83. doi: 10.5888/pcd11.130378. PMID 24831287

Trottier J, Perreault M, Rudkowska I, Levy C, Dallaire-Theroux A, Verreault M, Caron P, Staels B, Vohl MC, Straka RJ, Barbier O.Profiling serum bile acid glucuronides in humans: gender divergences, genetic determinants, and response to fenofibrate.Clin Pharmacol Ther. 2013 Oct;94(4):533-43. doi: 10.1038/clpt.2013.122. Epub 2013 Jun 12. PMID 23756370

Aslibekyan S, Straka RJ, Irvin MR, Class SA, Arnett DK.Pharmacogenomics of high-density lipoprotein-cholesterol-raising therapies. Expert Rev Cardiovasc Ther. 2013 Mar;11(3):355-64. doi: 10.1586/erc.12.134. PMID 23469915

Frazier-Wood AC1, Aslibekyan S, Borecki IB, Hopkins PN, Lai CQ, Ordovas JM, Straka RJ, Tiwari HK, Arnett DK.Genome-wide association study indicates variants associated with insulin signaling and inflammation mediate lipoprotein responses to fenofibrate. Pharmacogenet Genomics. 2012 Oct;22(10):750-7. PMID 22890011

Frazier-Wood AC, Ordovas JM, Straka RJ, Hixson JE, Borecki IB, Tiwari HK, Arnett DK.The PPAR alpha gene is associated with triglyceride, low-density cholesterol and inflammation marker response to fenofibrate intervention: the GOLDN study. Pharmacogenomics J. 2013 Aug;13(4):312-7. doi: 10.1038/tpj.2012.9. Epub 2012 May 1. PMID 22547144

Aslibekyan S, Kabagambe EK, Irvin MR, Straka RJ, Borecki IB, Tiwari HK, Tsai MY, Hopkins PN, Shen J, Lai CQ, Ordovas JM, Arnett. DKA genome-wide association study of inflammatory biomarker changes in response to fenofibrate treatment in the Genetics of Lipid Lowering Drug and Diet Network.
Pharmacogenet Genomics. 2012 Mar;22(3):191-7. doi: 10.1097/FPC.0b013e32834fdd41. PMID 22228203

Trottier J, Białek A, Caron P, Straka RJ, Heathcote J, Milkiewicz P, Barbier O.Metabolomic profiling of 17 bile acids in serum from patients with primary biliary cirrhosis and primary sclerosing cholangitis: a pilot study. Dig Liver Dis. 2012 Apr;44(4):303-10. doi: 10.1016/j.dld.2011.10.025. Epub 2011 Dec 9. PMID 22169272

Trottier J, Caron P, Straka, RJ, Barbier O. Profile of Serum Bile Acids in Noncholestatic Volunteers: Gender-Related Differences in Response to Fenofibrate. Clinical Pharmacology & Therapeutics. 2011August 90 (2):279-286 PMID 21716269

Kraja AT, Province MA, Straka RJ, Ordovas JM, Borecki IB, Arnett DK. Fenofibrate and metabolic syndrome.
Endocr Metab Immune Disord Drug Targets. 2010 Jun 1;10(2):138-48.PMID 20406163

Tsai MY, Ordovas JM, Li N, Straka RJ, Hanson NQ, Arends VL, Arnett D. Effect of fenofibrate therapy and ABCA1 polymorphisms on high-density lipoprotein subclasses in the Genetics of Lipid Lowering Drugs and Diet Network. Mol Genet Metab. 2010 Jun;100(2):118-22. Epub 2010 Mar 6.PMID: 20346718

Straka RJ, Liu LZ, Girase PS, DeLorenzo A, Chapman RH. Incremental cardiovascular costs and resource use associated with diabetes: an assessment of 29,863 patients in the US managed-care setting. Cardiovascular Diabetology. 2009 Sep 26;8:53. PMID: 19781099

Tojcic J, Benoit-Biancamano MO, Court MH, Straka RJ, Caron P, Guillemette C. In vitro glucuronidation of fenofibric acid by human UGTs and liver microsomes. Drug Metabolism and Disposition 2009;11:2236-2243. PMID 19661212

Perez-Martinez P, Corella D, Shen J, Arnett DK, Yiannakouris N, Tai ES, Orho-Melander M, Tucker KL, Tsai M, Straka RJ, Province M, Kai CS, Perez-Jimenez F, Lai CQ, Lopez-Miranda J, Guillen M, Parnell LD, Borecki I, Kathiresan S, Ordovas JM. Association between glucokinase regulatory protein (GCKR) and apolipoprotein A5 (APOA5) gene polymorphisms and triacylglycerol concentrations in fasting, postprandial, and fenofibrate-treated states. Am J Clin Nutr. 2009;89:391-399. PMID: 19056598

Liu Y, Ordovas JM, Gao G, Province M, Straka RJ, Tsai MY, Lai CQ, Zhang K, Borecki I, Hixson JE, Allison DB, Arnett DK. Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the Genetics of Lipid-Lowering Drugs and Diet Network study. Pharmacogenet Genomics. 2009;19:161-169. PMID: 19057464

Liu Y, Ordovas JM, Gao G. Province M. Straka RJ, Tsai MY, Lai CQ, Zhang K, Borecki I, Hixson JE, Allison DB, Arnett DK The SCARB1 gene is associated with lipid response to dietary and pharmacological interventions. Journal of Human Genetics 2008;53:709-717. PMID 18542840

Shen J. Arnett DK, Parnell LD, Peacock JM, Lai CQ, Hixon JE, Tsai MY, Province MA, Straka RJ, Ordovas JM. Association of common C-reactive protein (CRP) gene polymorphisms with baseline plasma CRP levels and fenofibrate response: The GOLDN Study. Diabetes Care. 2008;31:910-915. PMID: 18285551

Smith JA, Arnett DK, Kelly RJ, Ordovas JM, Sun YV, Hopkins PN, Hixson JE, Straka RJ, Peacock JM, Kardia SLR. The genetic architecture of fasting plasma triglyceride response to fenofibrate treatment. Euro J Hum Gen. 2008;16: 603-613. PMID: 18212815

Straka RJ, Mamdani M, Damen J, Kuntze CEE, Liu LZ, Botteman MF, Koren MJ. Economic impacts attributable to the early clinical benefit of atorvastatin therapy – a US managed care perspective. Curr Med Res Opin. 2007;23(7):1517-29. PMID: 17535539

Lai CQ, Arnett DK, Corella D, Straka, RJ, Tsai MY, Peacock JM, Adiconis X, Parnell LD, Hixon JE, Province MA, Ordovas JM. Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: The GOLDN study. Arterioscler Thromb Vasc Biol. 2007;27(6):1417-25. PMID: 17431185

Kaila N, Straka RJ, Brundage RC. Mixture models and subpopulation classification: A pharmacokinetic simulation study and application to metoprolol CYP2D6 phenotype. J Pharmacokinetics Pharmacodynamics. 2007;34(2):141-56. PMID: 17053980

Straka RJ, Burkhardt RT, Lang NP, Hadsall KZ, Tsai MY. Discordance between N-acetyltransferase 2 phenotype and genotype in a population of Hmong subjects. J Clin Pharmacol. 2006;46(7):802-11. PMID 16809806

Straka RJ, Burkhardt RT, Lang NP, Vang T, Hadsall KZ, Tsai MY Verified predominance of slow acetylator phenotype N-acetyltransferase 2 (NAT2) in a Hmong population residing in Minnesota. Biopharm Drug Dispos. 2006;27(6):299-304. PMID: 16799928

Straka RJ, Taheri R, Cooper SL, Smith JC. Achieving cholesterol target in a managed care organization (ACTION) trial. Pharmacotherapy. 2005;25(3):360-71. PMID: 15843283

Straka RJ, Taheri R, Cooper SL, Tan AW, Smith JC. Assessment of hypercholesterolemia control in a health care organization. Pharmacotherapy. 2001;21(7):818-27. PMID: 11444578

Straka RJ, Fish JP, Benson SR, Suh JT. Patient self-reporting of compliance does not correspond with electronic monitoring: an evaluation using isosorbide dinitrate as a model drug. Pharmacotherapy 1997:17(1);126-33. PMID: 9017773

Straka RJ, Hansen R, Walker P. Predominance of slow acetylators of N-acetyltransferase in a Hmong population residing in the United States. J Clin Pharmacol. 1996;36(8):740-7. PMID: 8877679

Straka RJ, Hansen RS, Walker PF. Comparison of the prevalence of the poor metabolizer phenotype for CYP2D6 between 203 Hmong subjects and 280 white subjects residing in Minnesota. Clin. Pharmacol Ther 1995;58(1):29-34. PMID: 7628180

Lalonde RL, Straka RJ, Pieper JA, Bottorff MB, Mirvis DM. Propranolol pharmacodynamic modeling using unbound and total concentrations in healthy volunteers. J Pharmacokinet Biopharm 1987;15(6):569-82. PMID: 3450842

Straka RJ, Lalonde RL, Pieper JA, Bottorff MB, Mirvis DM. Nonlinear pharmacokinetics of unbound propranolol after oral administration. J Pharm Sci 1987;76(7):521-4. PMID: 3668812
 

  • ©2014 Regents of the University of Minnesota. All rights reserved.
  • The University of Minnesota is an equal opportunity educator and employer
  • Last modified on October 9, 2014